Contineum Therapeutics, Inc. (NASDAQ: CTNM) is a Healthcare company (Biotechnology) with a market capitalization of $338M. The Maz Rating grades it against the other companies in its sector.
Contineum Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $9.55, Contineum Therapeutics, Inc. trades at 1.5x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -25.5%, return on invested capital of -28.8% and a free cash flow yield of -15.6%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 31.11. Over the past 52 weeks the share price ranged from $6.72 to $17.79, with a beta of 0.75.
Contineum Therapeutics, Inc. does not currently pay a dividend.
4 Wall Street analyst ratings cover the stock: 2 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Contineum Therapeutics, Inc. (CTNM) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.59% / 30% · (Cash+Inv) / Mkt Cap (36m) 52.7% / 30% · Interest income / Revenue 236200000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.59% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 52.7% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 236200000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.59% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 52.7% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 236200000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.26% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 94.7% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 236200000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 1.06% / 33.33% · (Cash+ST Inv) / Total Assets 95.1% / 33.33% · (Cash+Recv) / Total Assets 95.1% / 33.33% · Interest income / Revenue 236200000.0% / 5% | Fail |
No. As of September 2026, Contineum Therapeutics, Inc. (CTNM) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Contineum Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 236200000.0% of each dividend: Contineum Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.